Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy slows the rate at which your stomach empties its contents into the small intestine — a deliberate part of how the medicine reduces appetite and helps with weight loss. This gastric-emptying delay is not a side effect to be alarmed about, but it does affect practical decisions: when to eat, how to take other medicines, and what to tell a surgeon or anaesthetist before any procedure. Wegovy (semaglutide 2.4 mg, manufactured by Novo Nordisk) is a once-weekly injection licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. Because it is a prescription-only medicine, a prescriber assesses your full picture before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors, which exist not only in the brain and pancreas but also in the gut wall itself. One consequence of that activation is a reduction in the wave-like muscle contractions that push food through the stomach. The result is a slower, more gradual trickle of nutrients into the small intestine.
That slower transit is genuinely useful. It extends the feeling of fullness after a meal, smooths out blood-sugar rises after eating, and reduces the drive to snack. In the STEP 1 clinical trial, published in the New England Journal of Medicine, participants using semaglutide 2.4 mg lost around 15% of their body weight on average over 68 weeks, and the gastric-slowing mechanism is a meaningful part of why appetite falls so reliably. The NHS medicines page on semaglutide covers this mechanism in plain language if you want to read the patient-level overview.
The practical point is that the stomach behaves differently on Wegovy than it did before. Smaller portions feel satisfying sooner. Eating past that point can lead to nausea or discomfort, not because something has gone wrong, but because the stomach is holding more for longer. Starting at the lowest dose (0.25 mg) and titrating gradually gives the body time to adjust. Most people find the nausea and early fullness settle within a few weeks of each dose step.
For a fuller picture of how semaglutide works as a treatment, the semaglutide overview on our site covers the mechanism alongside the licensed schedule.
Once you understand that your stomach is working more slowly, several practical choices become clearer rather than more worrying.
Meals work better when they are smaller and eaten more slowly. High-fat meals are digested slowly at the best of times; when gastric emptying is already reduced, a large fatty meal can sit heavily for hours. Many people find protein-forward meals with plenty of vegetables and fibre feel best, not because there is a strict dietary rule, but because those foods tend to move through the system more comfortably. Your prescriber or a registered dietitian can give you specific guidance.
The more significant decision involves oral medicines. Because food and tablets both pass through the stomach at a slower rate, absorption of some oral drugs can be altered. This is particularly relevant for medicines with narrow therapeutic windows (anticoagulants, thyroid hormones, contraceptive pills) where even modest changes in absorption can matter. The full detail on what Wegovy can delay covers this in more depth. The practical step is straightforward: tell your GP and pharmacist you are on Wegovy, and have that conversation before you start any new medicine.
NHS England's guidance on weight-management injections explicitly flags the need to inform your healthcare team, including any prescriber or clinician managing other conditions, before and during treatment.
This is the area where the gastric-emptying effect carries the most immediate clinical weight. General anaesthesia requires an empty stomach, because regurgitation during a procedure (where stomach contents enter the airway) can be seriously dangerous. When gastric emptying is delayed, the stomach may still contain food or liquid even after the standard fasting period that most surgical teams expect patients to follow.
The NHS England guidance on weight-management injections is direct on this point: tell your surgeon, anaesthetist and the whole care team that you are using a GLP-1 medicine before any procedure. In practice, many anaesthetic teams now ask about GLP-1 medicines as a routine pre-operative question, and some surgical units ask patients to hold the injection for a week or more before a planned operation. That is a decision for your surgical and prescribing team jointly, not something to manage yourself by quietly skipping a dose.
If you are planning an operation and have questions about how to manage your Wegovy in the run-up, our prescribers are available seven days a week. The detailed page on whether Wegovy delays gastric emptying pulls together the clinical evidence on this specific question, and is worth reading before that conversation with your surgical team. If you have had a procedure recently and are wondering about restarting, that too is something to raise directly with a clinician rather than deciding alone.
It is also worth noting that some people worry about related digestive effects, like stomach inflammation. If reflux or upper abdominal discomfort is a concern, the page on Wegovy and gastritis addresses what the evidence actually shows.
Delayed gastric emptying sounds alarming as a phrase. In clinical practice, for most people on Wegovy, it simply means eating smaller portions, being thoughtful about timing around other medicines, and flagging it to any clinician who is treating you for something else. It is not a signal that the medicine is damaging your stomach.
The cases where it deserves more attention are specific: known gastroparesis (a condition involving severely impaired gastric motility) is a reason to discuss Wegovy very carefully with a prescriber before starting, and is one of the clinical factors reviewed at consultation. A history of certain gastrointestinal conditions is similarly worth discussing openly.
If you are weighing up whether Wegovy fits your situation (including other medicines you take, your surgical history, or conditions that affect your gut) the broader look at how Wegovy affects gastric emptying covers the nuance. Cost is a practical factor for many people too; the Wegovy prices page explains what private treatment typically involves. And if you have questions about other ways the medicine can affect your cycle or other body systems, the page on Wegovy and periods is worth a look.
Treatment through a regulated service means those individual factors get reviewed properly. At nume, every consultation is read by a GPhC-registered prescriber (a real clinician, not automated software) before anything is approved or dispatched. If you would like that clinical conversation, you can speak to our prescribers through a free consultation, with no obligation to proceed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.